Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Heart Fail Rev ; 29(5): 969-988, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38990214

RESUMO

Cancer is the leading cause of death worldwide, and the number of cancer-related deaths is expected to increase. Common types of cancer include skin, breast, lung, prostate, and colorectal cancers. While clinical research has improved cancer therapies, these treatments often come with significant side effects such as chronic fatigue, hair loss, and nausea. In addition, cancer treatments can cause long-term cardiovascular complications. Doxorubicin (DOX) therapy is one example, which can lead to decreased left ventricle (LV) echocardiography (ECHO) parameters, increased oxidative stress in cellular level, and even cardiac fibrosis. The apelinergic system, specifically apelin and its receptor, together, has shown properties that could potentially protect the heart and mitigate the damages caused by DOX anti-cancer treatment. Studies have suggested that stimulating the apelinergic system may have therapeutic benefits for heart damage induced by DOX. Further research in chronic preclinical models is needed to confirm this hypothesis and understand the mechanism of action for the apelinergic system. This review aims to collect and present data on the effects of the apelinergic system on doxorubicin-induced cardiotoxicity.


Assuntos
Antibióticos Antineoplásicos , Apelina , Cardiotoxicidade , Doxorrubicina , Humanos , Doxorrubicina/efeitos adversos , Cardiotoxicidade/etiologia , Antibióticos Antineoplásicos/efeitos adversos , Apelina/metabolismo , Animais , Estresse Oxidativo/efeitos dos fármacos , Neoplasias/tratamento farmacológico , Receptores de Apelina/metabolismo
2.
Int J Mol Sci ; 25(20)2024 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-39456833

RESUMO

There is little research concerning the role of stem cells in necrotizing enterocolitis (NEC). Bone marrow-derived mesenchymal stem cells (BMDSC) and amniotic fluid-derived stem cells significantly reduced the amount and severity of NEC in the animal models. ADSCs share similar surface markers and differentiation potential with BMDSCs. Their potential role in the setting of NEC has not been researched before. The hypothesis of the study was that prophylactic intraperitoneal administration of ADSCs before the onset of the disease will result in limiting the inflammatory response, effecting a lower incidence of NEC. On a molecular level, this should result in lowering the levels of inflammatory cytokines IL-1 and IL-6. The local ethical committee for animal experiments approval was acquired (WAW2/093/2021). We utilized a self-modified rat NEC model based on single exposure to hypothermia, hypoxia, and formula feeding. One hundred and twenty-eight rat puppies were divided into two groups-prophylaxis (ADSC-NEC, n = 66) and control group (NEC-PLCB, n = 62)-to measure the influence of ADSCs administration on the inflammatory changes in NEC, the level of cell engraftment, and the histopathology of the disease. The analysis did not show a significant effect on histopathology between groups, H(2) = 2.12; p = 0.347; η²H = 0.00. The intensity of the NEC variable results was similar across the analyzed groups (NEC-PLCB and ADSC-NEC). For IL-1 and IL-6, the difference between the NEC-PLCB group and the ADSC-NEC group was statistically significant, p = 0.002 and p < 0.001, respectively. To conclude, administration of adipose tissue-derived stem cells before the onset of the disease lowers the levels of inflammatory cytokines IL-1 and IL-6 but does not affect the histopathological results in the rat model of NEC.


Assuntos
Tecido Adiposo , Modelos Animais de Doenças , Enterocolite Necrosante , Interleucina-1 , Interleucina-6 , Animais , Enterocolite Necrosante/metabolismo , Enterocolite Necrosante/patologia , Ratos , Interleucina-6/metabolismo , Tecido Adiposo/citologia , Tecido Adiposo/metabolismo , Interleucina-1/metabolismo , Transplante de Células-Tronco Mesenquimais/métodos , Ratos Sprague-Dawley , Células-Tronco Mesenquimais/metabolismo , Transplante de Células-Tronco/métodos
3.
Immunol Res ; 72(4): 554-565, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38446328

RESUMO

Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination and damage to the central nervous system. It is well known, the significance of the involvement and influence of the immune system in the development and course of MS. Nowadays, more and more studies are demonstrating that an important factor that affects the action of the immune system is the gut microbiota. Changes in the composition and interrelationships in the gut microbiota have a significant impact on the course of MS. Dysbiosis affects the disease course mainly by influencing the immune system directly but also by modifying the secreted metabolites and increasing mucosal permeability. The essential metabolites affecting the course of MS are short-chain fatty acids, which alter pro- and anti-inflammatory responses in the immune system but also increase the permeability of the intestinal wall and the blood-brain barrier. Dietary modification alone can have a significant impact on MS. Based on these interactions, new treatments for MS are being developed, including probiotics administration, supplementation of bacterial metabolites, fecal microbiota transplantation, and dietary changes. Further studies may serve to develop new drugs and therapeutic approaches for MS.


Assuntos
Disbiose , Transplante de Microbiota Fecal , Microbioma Gastrointestinal , Esclerose Múltipla , Probióticos , Humanos , Microbioma Gastrointestinal/imunologia , Esclerose Múltipla/imunologia , Esclerose Múltipla/microbiologia , Esclerose Múltipla/terapia , Animais , Disbiose/imunologia , Probióticos/uso terapêutico , Probióticos/administração & dosagem , Barreira Hematoencefálica/imunologia , Barreira Hematoencefálica/metabolismo , Ácidos Graxos Voláteis/metabolismo
4.
Pharmacol Rep ; 76(3): 439-451, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38568371

RESUMO

Neurodegenerative diseases, which occur when neurons begin to deteriorate, affect millions of people worldwide. These age-related disorders are becoming more common partly because the elderly population has increased in recent years. While no treatments are accessible, every year an increasing number of therapeutic and supportive options become available. Various substances that may have neuroprotective effects are currently being researched. One of them is apelin. This review aims to illustrate the results of research on the neuroprotective effect of apelin amino acid oligopeptide which binds to the apelin receptor and exhibits neuroprotective effects in the central nervous system. The collected data indicate that apelin can protect the central nervous system against injury by several mechanisms. More studies are needed to thoroughly investigate the potential neuroprotective effects of this peptide in neurodegenerative diseases and various other types of brain damage.


Assuntos
Apelina , Peptídeos e Proteínas de Sinalização Intercelular , Doenças Neurodegenerativas , Fármacos Neuroprotetores , Humanos , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/uso terapêutico , Animais , Apelina/farmacologia , Apelina/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/farmacologia , Peptídeos e Proteínas de Sinalização Intercelular/uso terapêutico , Doenças Neurodegenerativas/tratamento farmacológico , Receptores de Apelina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA